Patents by Inventor Falk Nimmerjahn

Falk Nimmerjahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20230121427
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 20, 2023
    Inventors: Jeffrey V. Ravetch, Yoshikatsu Kaneko, Falk Nimmerjahn
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20220162290
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 26, 2022
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20210101961
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ?2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 8, 2021
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20200385443
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
    Type: Application
    Filed: December 20, 2019
    Publication date: December 10, 2020
    Inventors: Jeffrey V. Ravetch, Yoshikatsu Kaneko, Falk Nimmerjahn
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20190127446
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ?2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 2, 2019
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20190031737
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20190031738
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 31, 2019
    Inventors: Jeffrey V. Ravetch, Yoshikatus Kaneko, Falk Nimmerjahn
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20170320935
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: June 21, 2017
    Publication date: November 9, 2017
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20170283492
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 5, 2017
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20170218050
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 3, 2017
    Inventors: Jeffrey V. Ravetch, Yoshikatus Kaneko, Falk Nimmerjahn
  • Treatment for IgE-mediated disease
    Patent number: 9707279
    Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: July 18, 2017
    Assignee: Hansa Medical AB
    Inventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20170088608
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 30, 2017
    Inventors: Jeffrey V. Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20160176950
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ?2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: February 17, 2015
    Publication date: June 23, 2016
    Inventors: Jeffrey Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
    Publication number: 20140323696
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
    Type: Application
    Filed: May 16, 2014
    Publication date: October 30, 2014
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Yoshikatsu Kaneko, Falk Nimmerjahn
  • TREATMENT FOR IgE-MEDIATED DISEASE
    Publication number: 20140065128
    Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.
    Type: Application
    Filed: March 5, 2012
    Publication date: March 6, 2014
    Applicant: HANSA MEDICAL AB
    Inventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn
  • POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS
    Publication number: 20130273040
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ?2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: May 16, 2013
    Publication date: October 17, 2013
    Inventors: Jeffrey V. Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
    Patent number: 8470318
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2, 6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: June 25, 2013
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • Method of assessing glycosylation state or functional quality of an IgG containing sample
    Patent number: 8323908
    Abstract: The inventions provides methods and kits for the dissociation of Fc?-receptor-IgG complexes, and methods and kits for the isolation of IgG and Fc and Fab fragments of IgG.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: December 4, 2012
    Assignee: Genovis AB
    Inventors: Maria Allhorn, Anders Olin, Falk Nimmerjahn, Mattias Collin
  • POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS
    Publication number: 20120134988
    Abstract: The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided.
    Type: Application
    Filed: December 23, 2011
    Publication date: May 31, 2012
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Jeffrey V. Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko
  • POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS
    Publication number: 20110150867
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.
    Type: Application
    Filed: December 12, 2008
    Publication date: June 23, 2011
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Jeffrey V. Ravetch, Yoshikatsu Kaneko, Falk Nimmerjahn